ONCO — Stock Film
STOCK FILMSCENE 1/11ONCO · $0.67
Stock Expert AI presents
ONCO
Onconetix, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Onconetix, Inc. A quick introduction.

On the stock market since 2022, it operates in the world of health and science. It has 8 employees. Now — the numbers.

on the stock market since 2022
8 employees
$274K market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $18.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$0
DEBT: $49K
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

Every quarter, analysts set a profit bar.
How many of the last 4 did the company clear?
4 / 4
EXPECTATIONS MET OR BEATEN
4
Jun 2025
Jun 2025
Aug 2025
Aug 2026
4 TIMES IN THE LAST 4 QUARTERS
It clears the bar, quarter after quarter.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
12
very weak

Clearly below the class average.

FINANCIAL STRENGTH
11
very weak

Clearly below the class average.

VALUATION
58
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
40
weak

Clearly below the class average.

PRICE MOMENTUM
8
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Executives are buying stock8/10
WEAK SPOTS
Growth has stalled2/10
The stock has lost its spark2/10
Heavy bets against the stock3/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
The product is selling

Sales run at $815K a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 12 buys and 4 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $14.0M against $815K in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/3
Trading under $1

The stock sits at $0.67. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

3
THE RISKS · 3/3
A wildly swinging price

This stock swings about 2.7 times as much as the market average. Big rallies — and big drops — can both happen fast.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, ONCO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: ONCO is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film